BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 25315281)

  • 21. A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.
    Borodovsky A; Meeker AK; Kirkness EF; Zhao Q; Eberhart CG; Gallia GL; Riggins GJ
    J Neurooncol; 2015 Feb; 121(3):479-87. PubMed ID: 25471051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
    Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
    Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.
    Minasi S; Baldi C; Gianno F; Antonelli M; Buccoliero AM; Pietsch T; Massimino M; Buttarelli FR
    Childs Nerv Syst; 2021 Mar; 37(3):809-818. PubMed ID: 33128602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
    Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
    Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide small noncoding RNA profiling of pediatric high-grade gliomas reveals deregulation of several miRNAs, identifies downregulation of snoRNA cluster HBII-52 and delineates H3F3A and TP53 mutant-specific miRNAs and snoRNAs.
    Jha P; Agrawal R; Pathak P; Kumar A; Purkait S; Mallik S; Suri V; Chand Sharma M; Gupta D; Suri A; Sharma BS; Julka PK; Kulshreshtha R; Sarkar C
    Int J Cancer; 2015 Nov; 137(10):2343-53. PubMed ID: 25994230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis.
    Fogli A; Demattei MV; Corset L; Vaurs-Barrière C; Chautard E; Biau J; Kémény JL; Godfraind C; Pereira B; Khalil T; Grandin N; Arnaud P; Charbonneau M; Verrelle P
    J Neurooncol; 2017 Nov; 135(2):381-390. PubMed ID: 28755323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Constitutional mosaicism of a de novo TP53 mutation in a patient with bilateral choroid plexus carcinoma.
    Trubicka J; Filipek I; Iwanowski P; Rydzanicz M; Grajkowska W; Piekutowska-Abramczuk D; Chrzanowska K; Karkucińska-Więckowska A; Iwanicka-Pronicka K; Pronicki M; Łastowska M; Płoski R; Dembowska-Bagińska B
    Cancer Genet; 2017 Oct; 216-217():79-85. PubMed ID: 29025599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010.
    Gozali AE; Britt B; Shane L; Gonzalez I; Gilles F; McComb JG; Krieger MD; Lavey RS; Shlien A; Villablanca JG; Erdreich-Epstein A; Dhall G; Jubran R; Tabori U; Malkin D; Finlay JL
    Pediatr Blood Cancer; 2012 Jun; 58(6):905-9. PubMed ID: 21990040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations of the TP53 gene in human gliomas.
    Rasheed BK; McLendon RE; Herndon JE; Friedman HS; Friedman AH; Bigner DD; Bigner SH
    Cancer Res; 1994 Mar; 54(5):1324-30. PubMed ID: 8118823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Finkelstein SD; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Finlay JL; Sposto R;
    Cancer Res; 2001 Oct; 61(20):7404-7. PubMed ID: 11606370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
    Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
    Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma.
    Chen YJ; Hakin-Smith V; Teo M; Xinarianos GE; Jellinek DA; Carroll T; McDowell D; MacFarlane MR; Boet R; Baguley BC; Braithwaite AW; Reddel RR; Royds JA
    Cancer Res; 2006 Jul; 66(13):6473-6. PubMed ID: 16818615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternative lengthening of telomeres does exist in various canine sarcomas.
    Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
    Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 35. [Expression of hRad21 and clinicopathological analysis in gastrointestinal malignant tumors maintained their telomeres by a mechanism of alternative lengthening of telomeres].
    Yi BQ; Zhao B; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan; 11(1):67-71. PubMed ID: 18197499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of germline TP53 mutations and history of Li-Fraumeni syndrome in families with childhood adrenocortical tumors, choroid plexus tumors, and rhabdomyosarcoma: a population-based survey.
    Magnusson S; Gisselsson D; Wiebe T; Kristoffersson U; Borg Å; Olsson H
    Pediatr Blood Cancer; 2012 Nov; 59(5):846-53. PubMed ID: 22653678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
    Lee J; Solomon DA; Tihan T
    J Neurooncol; 2017 Mar; 132(1):1-11. PubMed ID: 28064387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.
    Grandin N; Pereira B; Cohen C; Billard P; Dehais C; Carpentier C; Idbaih A; Bielle F; Ducray F; Figarella-Branger D; Delattre JY; Sanson M; Lomonte P; Poncet D; Verrelle P; Charbonneau M;
    Acta Neuropathol Commun; 2019 Nov; 7(1):175. PubMed ID: 31706351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.
    Dorris K; Sobo M; Onar-Thomas A; Panditharatna E; Stevenson CB; Gardner SL; Dewire MD; Pierson CR; Olshefski R; Rempel SA; Goldman S; Miles L; Fouladi M; Drissi R
    J Neurooncol; 2014 Mar; 117(1):67-76. PubMed ID: 24477622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.